| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income | 1,342 | 1,701 | 2,123 | 2,735 |
| Net loss | -35,710 | -36,952 | -34,127 | -29,887 |
| Net loss per share, basic | -0.28 | -0.28 | -0.26 | -0.25 |
| Net loss per share, diluted | -0.28 | -0.28 | -0.26 | -0.25 |
| Weighted-average common shares outstanding, basic | 129,835,938 | 129,730,451 | 129,678,572 | 118,700,362 |
| Weighted-average common shares outstanding, diluted | 129,835,938 | 129,730,451 | 129,678,572 | 118,700,362 |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)